Osteopontin levels in an asbestos-exposed population

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1362-1366

  Park, Eun Kee ^a,b   Thomas, Paul S ^b   Johnson, Anthony R ^a   Yates, Deborah H ^a,c  

^a Research and Education Unit   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; OSTEOPONTIN;

ARTICLE; ASBESTOSIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA PLAQUE; PLEURA THICKENING; PRIORITY JOURNAL; SILICOSIS; AGED; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PROSPECTIVE STUDY;

AGED; ASBESTOS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; OSTEOPONTIN; PROSPECTIVE STUDIES;

EID: 63149105992     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0360     Document Type: Article

References (25)

1. Howel D, Gibbs A. Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region. Occup Environ Med 1999:56:51 -8.
2. Agudo A, Gonzalez CA, Bleda MJ. Occupation and risk of malignant pleural mesothelioma: a case-control study in Spain. Am J Ind Med 2000:37:159-68.
3. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004;14:479 -87.
4. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591 -603.
5. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997;6: 162-6.
6. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-93.
7. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113:66-73S.
8. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5: 290-8.
9. Hyland RA, Ware S, Johnson AR, Yates DH. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33:286-92.
10. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79:666-72.
11. Clements M, Berry G, Shi J, Ware S, Yates D, Johnson A. Projected mesothelioma incidence in men in New South Wales. Occup Environ Med 2007;64: 742-52.
12. Scherpereel A, Lee YCG. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-43.
13. Robinson BWS, Creaney J, Lake R, et al. Meso-thelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
14. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564 - 73.
15. Scherpereel A, Grigorlu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
16. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-35.
17. Weber CF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
18. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-41.
19. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
20. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002:287:1671-9.
21. Brakora KA, Lee H, Yusuf R, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004:93:361 -5.
22. American Thoracic Society. Diagnosis and management of non-malignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691-715.
23. Treasure T, Waller D, Swift S, Peto J. Radical surgery for mesothelioma. BMJ 2004;328:237-8.
24. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer: a critique of the Mayo Lung Project. Cancer1991;67:1155-64.
25. O'Regan AW, Serlin D, Berman JS. Asbestos exposure and serum osteopontin. N Engl J Med 2006:354: 304-5.